Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study

F Bes , W Hofman, J Schuur, C Van Boxtel

Affiliations Expand

• PMID: 1299794
• DOI: 10.1159/000118919

Abstract

The influence of delta sleep-inducing peptide (DSIP) on sleep was studied in 16 chronic insomniac patients according to a double-blind matched-pairs parallel-groups design. Subjects slept for 5 consecutive nights in the laboratory. Night 1 was used for adaptation, night 2 for baseline measurements. In the afternoon before the 3rd, 4th and 5th night, half of the patients received intravenously 25 nmol/kg body weight DSIP, and half of the patients a glucose solution (placebo). Measures for sleep structure, objective (polysomnography) and subjective sleep quality and for subjective tiredness were assessed. The results for objective sleep quality indicated higher sleep efficiency and shorter sleep latency with DSIP as compared to placebo. One measure of subjectively estimated tiredness decreased within the DSIP group. Data analysis suggested, however, that the statistically significant effects were weak and in part could be due to an incidental change in the placebo group. As none of the other measures, including subjective sleep quality, showed any change, it was concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit.

**Disclaimer:** This article is intended for informational and educational purposes only. The content presented is a summary of existing scientific research and does not constitute medical or health advice. Ipamorelin is a research chemical and has not been approved by the FDA or other regulatory bodies for the diagnosis, treatment, cure, or prevention of any disease or condition. It is not intended for human consumption.

Is this article making health claims?
No. This article explicitly does not make any health or therapeutic claims. It is a summary of existing scientific research presented for informational and educational purposes only. The disclaimer at the beginning of the article is a critical part of this communication.